{"id":"risperidone-oral-tablets","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-15%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking these receptors, risperidone reduces the activity of dopamine and serotonin in the brain, which helps to alleviate symptoms of psychosis and mania. This mechanism of action is thought to be responsible for its therapeutic effects in treating schizophrenia and bipolar disorder.","oneSentence":"Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:17.882Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT07477301","phase":"PHASE2","title":"Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2024-12-01","conditions":"Schizophrenia, Cognitive Dysfunction, Inflamation","enrollment":46},{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT04105231","phase":"PHASE2","title":"Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lone Baandrup","startDate":"2021-06-01","conditions":"Dual Diagnosis","enrollment":64},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT06838104","phase":"NA","title":"Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-05","conditions":"Schizophrenia Disorders, Psychotic Disorder","enrollment":76},{"nctId":"NCT05779241","phase":"PHASE3","title":"Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2023-04-13","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":83},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT05401019","phase":"PHASE2","title":"Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)","status":"WITHDRAWN","sponsor":"Clinical Academic Center (2CA-Braga)","startDate":"2022-06","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT03055338","phase":"PHASE2","title":"An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-08","conditions":"Schizophrenia, Acute Episode","enrollment":224},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT04094207","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-01-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT05179525","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone.","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2021-03-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03230864","phase":"PHASE3","title":"Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2017-07-20","conditions":"Treatment-resistant Schizophrenia","enrollment":119},{"nctId":"NCT02717195","phase":"PHASE3","title":"Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-04","conditions":"Schizophrenia","enrollment":1098},{"nctId":"NCT03790085","phase":"EARLY_PHASE1","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2018-09-01","conditions":"Schizophrenia, Major Depressive Disorder, Anxiety Disorders","enrollment":2700},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT03220867","phase":"PHASE1","title":"Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants","status":"WITHDRAWN","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-12-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT02758067","phase":"PHASE3","title":"Comparison of the Effectiveness of Brexpiprazole With That of Risperidone","status":"WITHDRAWN","sponsor":"H. Lundbeck A/S","startDate":"2016-06","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01670071","phase":"PHASE4","title":"A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2013-01","conditions":"Schizophrenia","enrollment":17},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT01592201","phase":"PHASE4","title":"A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-07","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00910780","phase":"PHASE2, PHASE3","title":"Metabolic Effects of Antipsychotic Substitution in Children","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Diabetes","enrollment":""},{"nctId":"NCT00992407","phase":"PHASE4","title":"An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-12","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00934635","phase":"PHASE4","title":"A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls","status":"TERMINATED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2009-09","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT02012049","phase":"PHASE1","title":"Bioequivalence Test for Risperdal 2mg of Janssen Korea","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2009-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT00857818","phase":"PHASE3","title":"Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-04","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder","enrollment":64},{"nctId":"NCT01010776","phase":"PHASE4","title":"A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2008-02","conditions":"Schizophrenia","enrollment":223},{"nctId":"NCT00237913","phase":"PHASE3","title":"Schizophrenia Trial of Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":700},{"nctId":"NCT00232687","phase":"PHASE4","title":"A Switch Study of BMS-337039 in Schizophrenic Out-patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-06","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT00604279","phase":"PHASE3","title":"A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":452},{"nctId":"NCT01607762","phase":"PHASE1","title":"A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT01207414","phase":"PHASE4","title":"Switching to Iloperidone From Other Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Schizophrenia","enrollment":501},{"nctId":"NCT01129674","phase":"PHASE2, PHASE3","title":"A Long-Term, Open-Label, Study on Schizophrenia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2010-06","conditions":"Schizophrenia","enrollment":1210},{"nctId":"NCT00600756","phase":"PHASE3","title":"Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Schizophrenic Disorders","enrollment":798},{"nctId":"NCT00086112","phase":"PHASE3","title":"Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Anxiety Disorders","enrollment":301},{"nctId":"NCT00257075","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-12","conditions":"Bipolar Disorders, Manic Episode","enrollment":267},{"nctId":"NCT00249236","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-03","conditions":"Bipolar Disorder, Manic Episode","enrollment":291},{"nctId":"NCT01222923","phase":"NA","title":"Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":40},{"nctId":"NCT01222975","phase":"NA","title":"Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT01155921","phase":"PHASE1","title":"Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01155934","phase":"PHASE1","title":"Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00645502","phase":"PHASE1","title":"Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-06","conditions":"Schizophrenia, Schizoaffective Disorders","enrollment":40},{"nctId":"NCT00893256","phase":"PHASE4","title":"Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia","status":"COMPLETED","sponsor":"National Institute of Mental Health and Neuro Sciences, India","startDate":"2004-12","conditions":"Schizophrenia, Negative Symptoms","enrollment":48},{"nctId":"NCT00480844","phase":"PHASE4","title":"Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2008-10","conditions":"Schizophrenia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Risperidone, oral tablets","genericName":"Risperidone, oral tablets","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. Used for Schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}